Reiteration Archives - Page 30 of 399

2 minute read

JD.Com’s Cost Management In Focus – Analyst Maintains Core GMV Growth Assumptions

April 16, 2:10 PM

Analyst maintains Buy rating on JD.com, anticipating core GMV growth and earnings upside from disciplined cost management amidst healthy China retail/e-commerce growth.

2 minute read

Goldman Sachs Boasts ‘Near-Perfect’ Q1 Results, 5 Analysts Zero In On ‘Core Strengths’

By Priya Nigam

April 16, 12:09 PM

Goldman Sachs Group Inc (NYSE: GS) and other financial stocks have been in focus as some of the sector’s biggest banks report first-quarter results.

2 minute read

Charles Schwab Positions For ‘More Robust EPS Growth’: Analysts Weigh In On Q1 Results

By Priya Nigam

April 16, 12:02 PM

Charles Schwab Corporation (NYSE: SCHW) shares remained volatile in early trading on Tuesday, after the company reported its first-quarter earnings.

SCHW

2 minute read

Is Apple About To Disappoint Investors With Q2 Print? Analyst Flags 2 Factors Weakening iPhone Maker

By Shanthi Rexaline

April 16, 8:14 AM

Needham now estimates second-quarter sales of $90.8 billion, marking a 4% year-over-year drop.

AAPL

2 minute read

Nvidia’s Hopper Demand and Blackwell Launch Position Makes It A Top Large-Cap Pick: Analysts

By Anusuya Lahiri

April 15, 3:35 PM

Piper Sandler analyst reiterated Overweight rating on Nvidia with $1,050 target. Demand for Hopper GPU remains strong, Blackwell launch expected to face supply constraints. Nvidia leading AI market, facing challenges with high-power systems. NVDA shares down 1.81%.

NVDA

2 minute read

Micron Dominates High-Bandwidth Memory Market, Anticipates Significant Revenue Growth: Analyst

By Anusuya Lahiri

April 15, 1:26 PM

Kumar reiterates Overweight rating and $130 PT for Micron Technology, with promising insights into HBM market and commitment to innovation.

FEPI

2 minute read

Netflix Q1 Subscriber Estimates Too High? Analyst Cautions On Elevated Expectations, ‘How Big Is The Beat’ Mentality

By Chris Katje

April 12, 4:20 PM

After adding 13.12 million net subscriber adds in the fourth quarter, could expectations for Netflix be too high? An analyst weighs in.

NFLX

2 minute read

Small-Cap Cancer Drug Developer Agenus’ Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom

By Vandana Singh

April 12, 2:18 PM

The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.

AGEN